RPGLIFE Q4 FY26 Revenue up 23.6% to ₹176.9 Cr, Recommends 300% Dividend
RPG Life Sciences reported Q4 FY26 revenue of ₹176.9 crore, up 23.6% YoY, with an EBITDA margin of 25.6%. For FY26, revenue grew 8.3% to ₹707.5 crore. The DF business grew 18.2% in Q4 and 13.7% for FY26. The API division grew 144.3% in Q4. The company recommended a 300% dividend (₹24 per share).
The announcement includes strong financial performance metrics, significant business segment growth, and a substantial dividend recommendation, which are key factors that can positively impact investor sentiment and the company's stock.
The company reported strong year-on-year revenue growth in Q4 and for the full year, significant outperformance in its Domestic Formulation business, and a strong comeback in its API division. The recommendation of a substantial dividend further supports a positive sentiment.
RPG Life Sciences Limited announced its audited financial results for the financial year ended March 31, 2026. In the fourth quarter of FY26, the company's revenue from operations grew by 23.6% year-on-year to ₹176.9 crore, compared to ₹143.1 crore in Q4 FY25. The EBITDA margin for Q4 FY26 stood at a healthy 25.6%.
The Domestic Formulation (DF) business recorded robust growth of 18.2% in Q4 FY26, significantly outpacing the Indian Pharma Market (IPM) growth of 10.1%, positioning RPG Life Sciences as the 4th fastest-growing pharma company in India. The API division showed a strong comeback, registering a growth of 144.3% in Q4 FY26, attributed to the unit resuming operations after a fire incident in January 2025.
For the full financial year FY26, revenue from operations grew by 8.3% to ₹707.5 crore, compared to ₹653.4 crore in FY25, with a healthy EBITDA margin of 24.4%. The DF business contributed 70% of overall sales and delivered a market-beating 13.7% growth for FY26, against the IPM's 8.6%. Key portfolio baskets like nephrology, oncology, and pain management drove this growth.
Commenting on the results, Mr. Ashok Nair, Managing Director, stated that the company has built solid momentum driven by field effectiveness, operational discipline, and focus on key brands. He highlighted the resilience of the API business and outlined future plans to strengthen the new product pipeline, enhance brand equity, drive field force effectiveness, and widen the global footprint.
The Board of Directors, in their meeting held on April 29, 2026, recommended a Final dividend of ₹24 per equity share, which is 300% on the face value of ₹8 per share, for FY25-26, subject to shareholder approval.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.